---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-010526"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T05:10:21.615567+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Evofem Q1 net income $1.0M, revenue $0.8M; plans 55-60% PHEXXI COGS cut

## Summary
- Net sales $0.8M, down 78% from $3.6M YoY due to order timing after Q4 2024 stocking.
- Net income $1.0M ($0.01 basic EPS) vs net loss $4.9M ($0.16 loss) in Q1 2024.
- Partnered with Windtree to reduce PHEXXI manufacturing cost by 55-60%; Evofem bears no tech transfer costs.
- Received $1.5M in April from sale of notes/warrants to Aditxt under merger agreement.
- Cash and restricted cash $1.1M at March 31, 2025; new U.S. patent for SOLOSEC extends to 2040.

## SEC filing metadata
- accession: 0001641172-25-010526
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000164117225010526/0001641172-25-010526-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000164117225010526/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-010526
- JSON: https://secwatch.observer/filing/0001641172-25-010526.json
- Plain text: https://secwatch.observer/filing/0001641172-25-010526.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.